These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35354614)

  • 21. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.
    Calle RA; Amin NB; Carvajal-Gonzalez S; Ross TT; Bergman A; Aggarwal S; Crowley C; Rinaldi A; Mancuso J; Aggarwal N; Somayaji V; Inglot M; Tuthill TA; Kou K; Boucher M; Tesz G; Dullea R; Bence KK; Kim AM; Pfefferkorn JA; Esler WP
    Nat Med; 2021 Oct; 27(10):1836-1848. PubMed ID: 34635855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
    Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
    Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
    Newsome PN; Palmer M; Freilich B; Sheikh MY; Sheikh A; Sarles H; Herring R; Mantry P; Kayali Z; Hassanein T; Lee HM; Aithal GP;
    J Hepatol; 2020 Aug; 73(2):231-240. PubMed ID: 32234329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
    Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
    J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.
    Loomba R; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Harrison SA; Lawitz EJ; Gunn N; Imajo K; Ravendhran N; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Abdelmalek MF
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):102-112.e9. PubMed ID: 37088457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
    Abdelmalek MF; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Lawitz EJ; Harrison SA; Jacobson IM; Imajo K; Gunn N; Halegoua-DeMarzio D; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Loomba R
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):113-123.e9. PubMed ID: 37088458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
    Newsome PN; Buchholtz K; Cusi K; Linder M; Okanoue T; Ratziu V; Sanyal AJ; Sejling AS; Harrison SA;
    N Engl J Med; 2021 Mar; 384(12):1113-1124. PubMed ID: 33185364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
    Harrison SA; Bedossa P; Guy CD; Schattenberg JM; Loomba R; Taub R; Labriola D; Moussa SE; Neff GW; Rinella ME; Anstee QM; Abdelmalek MF; Younossi Z; Baum SJ; Francque S; Charlton MR; Newsome PN; Lanthier N; Schiefke I; Mangia A; Pericàs JM; Patil R; Sanyal AJ; Noureddin M; Bansal MB; Alkhouri N; Castera L; Rudraraju M; Ratziu V;
    N Engl J Med; 2024 Feb; 390(6):497-509. PubMed ID: 38324483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
    Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
    Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study.
    Abdelmalek MF; Suzuki A; Sanchez W; Lawitz E; Filozof C; Cho H; Baek E; Choi J; Baek S
    Contemp Clin Trials; 2023 Jul; 130():107176. PubMed ID: 37028504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.
    Anstee QM; Neuschwander-Tetri BA; Wong VW; Abdelmalek MF; Younossi ZM; Yuan J; Pecoraro ML; Seyedkazemi S; Fischer L; Bedossa P; Goodman Z; Alkhouri N; Tacke F; Sanyal A
    Contemp Clin Trials; 2020 Feb; 89():105922. PubMed ID: 31881392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.
    Amin NB; Carvajal-Gonzalez S; Purkal J; Zhu T; Crowley C; Perez S; Chidsey K; Kim AM; Goodwin B
    Sci Transl Med; 2019 Nov; 11(520):. PubMed ID: 31776293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study.
    Anstee QM; Neuschwander-Tetri BA; Wai-Sun Wong V; Abdelmalek MF; Rodriguez-Araujo G; Landgren H; Park GS; Bedossa P; Alkhouri N; Tacke F; Sanyal AJ
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):124-134.e1. PubMed ID: 37061109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
    Francque SM; Bedossa P; Ratziu V; Anstee QM; Bugianesi E; Sanyal AJ; Loomba R; Harrison SA; Balabanska R; Mateva L; Lanthier N; Alkhouri N; Moreno C; Schattenberg JM; Stefanova-Petrova D; Vonghia L; Rouzier R; Guillaume M; Hodge A; Romero-Gómez M; Huot-Marchand P; Baudin M; Richard MP; Abitbol JL; Broqua P; Junien JL; Abdelmalek MF;
    N Engl J Med; 2021 Oct; 385(17):1547-1558. PubMed ID: 34670042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    Bril F; Barb D; Lomonaco R; Lai J; Cusi K
    J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
    Ratziu V; Rinella ME; Neuschwander-Tetri BA; Lawitz E; Denham D; Kayali Z; Sheikh A; Kowdley KV; Desta T; Elkhashab M; DeGrauw J; Goodwin B; Ahmad A; Adda N
    J Hepatol; 2022 Mar; 76(3):506-517. PubMed ID: 34740705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
    Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
    Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.